Clinical Trial

Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Multi-national Trial. The Goal of the Trial is to Offer Subjects Who Complete 12 Months in the LUM-201-10 Phase 3 Trial up to an Additional 36 Months of Treatment of LUM-201 While Evaluating Safety and Tolerability of LUM-201.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-15.
Trial Details
NCT Number NCT07129759
Lead Sponsor Lumos Pharma
Conditions Growth Hormone Deficiency (GHD)
Enrollment 150 participants
Start Date 2027-02
Primary Completion 2030-02 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-08